| 摘要 |
<p>Use of potassium voltage channel (Kv) 1.5 inhibitors (I) for producing a medicament for the therapy or prophylaxis of e.g. respiratory disorders, upper airway resistance syndrome, Cheyne-Stokes respiration, snoring, disrupted central respiratory drive, sudden child death, postoperative hypoxia and apnea, respiratory disorders during adaptation in high mountains, neurodegenerative disorders, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cancer disorders, breast cancer, lung cancer, colon cancer and prostate cancer. Use of potassium voltage channel (Kv) 1.5 inhibitors (I) for producing a medicament for the therapy or prophylaxis of respiratory disorders, sleep-related respiratory disorders, central and obstructive sleep apneas, upper airway resistance syndrome, Cheyne-Stokes respiration, snoring, disrupted central respiratory drive, sudden child death, postoperative hypoxia and apnea, muscle-related respiratory disorders, respiratory disorders after long-term ventilation, respiratory disorders during adaptation in high mountains, acute and chronic lung disorders with hypoxia and hypercapnia, neurodegenerative disorders, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cancer disorders, breast cancer, lung cancer, colon cancer and prostate cancer. ACTIVITY : Respiratory-Gen.; CNS-Gen.; Vasotropic; Neuroprotective; Nootropic; Antiparkinsonian; Anticonvulsant; Cytostatic. MECHANISM OF ACTION : Task-1 channel inhibitor; Task-3 channel inhibitor; Potassium voltage channel inhibitor. (I) were tested for its Task-1 channel inhibitory activity using human Task-1 channels expressed in Xenopus oocytes. The results showed that the median inhibitory concentration of 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide was 0.10 mu mol.</p> |
